Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.53 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285885 | 0.81 | TAAR1 (0.46) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL12476008 | 0.77 | ACHE (0.50) | SLC13A5ALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL29773177 | 0.76 | HSD17B10 (0.70) | SLC13A5ALDH1A1SMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL13205866 | 0.76 | HSD17B10 (0.70) | SLC13A5ALDH1A1SMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL5104190 | 0.75 | MAPT (0.41) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL27919546 | 0.75 | ALDH1A1 (0.61) | PTGER4PTGER3PTGER2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5104193 | 0.75 | MAPT (0.41) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL28758229 | 0.75 | MAPT (0.43) | PTGER4PTGER3PTGER2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7092087 | 0.74 | KDM4E (0.62) | PTGER4PTGER3PTGER2ALDH1A1SMN1; SMN2 | |
| SCHEMBL18123531 | 0.74 | CYP19A1 (0.47) | SLC13A5ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | disclosed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-1851230-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | RAB1A, RAB7A, RAB35 | PTGER4 3967/4885PTGER3 2380/4885PTGER2 3482/4885 |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | MKI67, BCL2, BAX | PTGER4 1690/4885PTGER3 2602/4885PTGER2 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.